Adaptive Biotechnologies Corporation (ADPT): Price and Financial Metrics
ADPT Price/Volume Stats
| Current price | $2.64 | 52-week high | $9.08 |
| Prev. close | $2.51 | 52-week low | $2.28 |
| Day low | $2.45 | Volume | 662,926 |
| Day high | $2.73 | Avg. volume | 1,610,858 |
| 50-day MA | $3.32 | Dividend yield | N/A |
| 200-day MA | $4.81 | Market Cap | 383.04M |
ADPT Stock Price Chart Interactive Chart >
Adaptive Biotechnologies Corporation (ADPT) Company Bio
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
Latest ADPT News From Around the Web
Below are the latest news stories about Adaptive Biotechnologies Corp that investors may wish to consider to help them evaluate ADPT as an investment opportunity.
Adaptive Biotechnologies Corporation 2021 Q3 - Results - Earnings Call PresentationThe following slide deck was published by Adaptive Biotechnologies Corporation in conjunction with their 2021 Q3 earnings call.... |
Adaptive Biotechnologies EPS beats by $0.03, beats on revenueAdaptive Biotechnologies (NASDAQ:ADPT): Q3 GAAP EPS of -$0.40 beats by $0.03. Revenue of $39.5M (+50.2% Y/Y) beats by $2.87M. Press Release... |
ADPT Price Returns
| 1-mo | -18.52% |
| 3-mo | -36.08% |
| 6-mo | -40.61% |
| 1-year | -68.00% |
| 3-year | -93.87% |
| 5-year | N/A |
| YTD | -46.12% |
| 2023 | -35.86% |
| 2022 | -72.77% |
| 2021 | -52.55% |
| 2020 | 97.63% |
| 2019 | N/A |
Loading social stream, please wait...